Get started
Author

Hiroko Yamakawa

Observed names: Yamakawa, H., Yamakawa, Hiroko
ORCID: 0009-0003-5456-7643
Observed ORCID: 0009-0003-5456-7643
OpenAlex ID: A5079856870
Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: Modification of the core skeleton for improved solubility
2012 · Tomohiro Ohashi, Yuya Oguro, et al. · Bioorganic & Medicinal Chemistry · 72
Discovery of pyrrolo[3,2-c]quinoline-4-one derivatives as novel hedgehog signaling inhibitors
2012 · Tomohiro Ohashi, Yuya Oguro, et al. · Bioorganic & Medicinal Chemistry · 68
Synthesis and evaluation of hedgehog signaling inhibitor with novel core system
2015 · Tomohiro Ohashi, Yuta Tanaka, et al. · Bioorganic & Medicinal Chemistry · 6
Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents
2018 · Emiko Shinozawa, Yuichiro Amano, et al. · Pharmacology Research & Perspectives · 5
PDF
Farnesoid X receptor antagonist exacerbates dyslipidemia in mice
2017 · Yuichiro Amano, Hiroko Yamakawa, et al. · Pharmacological Reports · 5
CDK12/13 inhibitor, CTX-439, suppresses tumor growth and potentiates BCL-2 family blockade
2026 · Hiroko Yamakawa, Raghda Khatab, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 4
PDF
Abstract 2823: TAK-441, a novel investigational small molecule hedgehog pathway inhibitor for use in cancer therapy
2011 · Hideaki Tojo, Sachio Shibata, et al. · Cancer Research · 4
A Novel CDK12 Inhibitor Induces Homologous Recombination Deficiency to Enhance PARP Inhibitor Efficacy in Uterine Serous Carcinoma
2026 · Shunsuke Kawahara, Mana Taki, et al. · Molecular Cancer Therapeutics · 3
Abstract 1745: Combining HRI/PERK/GCN2 inhibitor CRD-799 with proteasome inhibitors provides a novel approach to overcoming resistance in multiple myeloma treatment
2025 · Yasumichi Inoue, Koki Hikami, et al. · Cancer Research · 2
Abstract 3301: Translational research of CDK12/13 inhibitor, CTX-439, informing clinical trial strategy
2024 · Hiroko Yamakawa, Shunsuke Ebara, et al. · Cancer Research · 2
Phosphorylation Dynamics and Kinase Interaction in mRNA Transcription-Associated Kinases: Autophosphorylation of CDK12 and its Modulation by CDK7 and CDK9
2024 · Hiroko Yamakawa, Shunsuke Ebara, et al. · BPB Reports · 2
PDF
Abstract 5485: Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor
2022 · Hiroko Yamakawa, Akio Mizutani, et al. · Cancer Research · 2
Abstract 1636: Novel CDK12/13 inhibitor CTX-439 downregulates MCL1 via transcriptional mRNA read-through and synergistically acts with BCL-XL inhibitors for cancer therapy
2025 · Hiroko Yamakawa, Raghda Khatab, et al. · Cancer Research · 1
Interaction of CDK12 with NXF1 is a new node for the linking mechanism between transcription and transportation of mRNA
2024 · Shunsuke Ebara, Misaki Yoshida, et al. · Biochemical and Biophysical Research Communications · 1
PDF
Abstract 1233: Novel inhibitor targeting triple integrated stress response kinase HRI, PERK, and GCN2 provides new insights into overcoming resistance to proteasome inhibitors in multiple myeloma
2024 · Yasumichi Inoue, Koki Hikami, et al. · Cancer Research · 1
Preclinical Translational Research Suggests a Clinical Trial Strategy for a Novel MALT1 Inhibitor ONO-7018/CTX-177 Against Malignant Lymphomas
2022 · Daisuke Morishita, Akio Mizutani, et al. · Blood · 1
Abstract 5389: Exploring potential predictive biomarkers for the responsiveness to CTX-712 by in vivo drug sensitivity analysis on PDX models
2022 · Daisuke Morishita, Shigehiro Yagishita, et al. · Cancer Research · 1
Discovery of CTX-439: A Potent and Selective CDK12 Inhibitor as a Prospective Anti-Cancer Drug
2026 · Kenichiro Shimokawa, Koji Ono, et al. · ACS Medicinal Chemistry Letters
CDK10 loss primes tumor cells for transcriptional vulnerability and sensitizes to CDK12/13 inhibition
2026 · Shafiqul Islam, Yusuke Tarumoto, et al. · Cell Death and Disease
PDF
CCDC 1028036: Experimental Crystal Structure Determination
2015 · Ohashi, Tomohiro, Tanaka, Yuta, et al. · The Cambridge Structural Database
CCDC 1027998: Experimental Crystal Structure Determination
2015 · Ohashi, Tomohiro, Tanaka, Yuta, et al. · The Cambridge Structural Database
CCDC 1027990: Experimental Crystal Structure Determination
2015 · Ohashi, Tomohiro, Tanaka, Yuta, et al. · The Cambridge Structural Database
CCDC 865214: Experimental Crystal Structure Determination
2013 · Ohashi, T., Oguro, Y., et al. · The Cambridge Structural Database
Works count: 23
Citation count: 180
H-index: 5
I10-index: 2
Year
Topic
Type